CY2017034I1 - Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη - Google Patents
Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινηInfo
- Publication number
- CY2017034I1 CY2017034I1 CY2017034C CY2017034C CY2017034I1 CY 2017034 I1 CY2017034 I1 CY 2017034I1 CY 2017034 C CY2017034 C CY 2017034C CY 2017034 C CY2017034 C CY 2017034C CY 2017034 I1 CY2017034 I1 CY 2017034I1
- Authority
- CY
- Cyprus
- Prior art keywords
- bendamustin
- defucosylated
- antibody
- combination therapy
- therapy
- Prior art date
Links
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 title 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09010489 | 2009-08-14 | ||
| EP10747168.2A EP2464382B1 (en) | 2009-08-14 | 2010-08-12 | Combination therapy of an afucosylated cd20 antibody with bendamustine |
| PCT/EP2010/004939 WO2011018224A1 (en) | 2009-08-14 | 2010-08-12 | Combination therapy of an afucosylated cd20 antibody with bendamustine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CY2017034I2 CY2017034I2 (el) | 2018-02-14 |
| CY2017034I1 true CY2017034I1 (el) | 2018-02-14 |
Family
ID=41351729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100706T CY1119251T1 (el) | 2009-08-14 | 2017-07-03 | Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη |
| CY2017034C CY2017034I1 (el) | 2009-08-14 | 2017-10-26 | Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100706T CY1119251T1 (el) | 2009-08-14 | 2017-07-03 | Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US20110165151A1 (el) |
| EP (1) | EP2464382B1 (el) |
| JP (3) | JP5646626B2 (el) |
| KR (1) | KR101425736B1 (el) |
| CN (2) | CN102596245A (el) |
| AR (1) | AR077866A1 (el) |
| AU (1) | AU2010281866B2 (el) |
| BR (1) | BR112012002855A2 (el) |
| CA (1) | CA2769674C (el) |
| CL (1) | CL2012000391A1 (el) |
| CR (1) | CR20120036A (el) |
| CY (2) | CY1119251T1 (el) |
| DK (1) | DK2464382T3 (el) |
| ES (1) | ES2630158T3 (el) |
| HK (1) | HK1245145A1 (el) |
| HR (1) | HRP20170972T1 (el) |
| HU (2) | HUE033531T2 (el) |
| IL (1) | IL217753A (el) |
| LT (2) | LT2464382T (el) |
| LU (1) | LUC00045I2 (el) |
| MA (1) | MA33469B1 (el) |
| MX (2) | MX355849B (el) |
| MY (1) | MY163003A (el) |
| NO (1) | NO2017054I1 (el) |
| NZ (1) | NZ597666A (el) |
| PL (1) | PL2464382T3 (el) |
| PT (1) | PT2464382T (el) |
| RS (1) | RS56146B1 (el) |
| SG (1) | SG178324A1 (el) |
| SI (1) | SI2464382T1 (el) |
| TW (1) | TWI409079B (el) |
| UA (1) | UA110096C2 (el) |
| WO (1) | WO2011018224A1 (el) |
| ZA (1) | ZA201200830B (el) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03330B (me) | 2003-11-05 | 2019-10-20 | Roche Glycart Ag | Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom |
| PE20140625A1 (es) | 2007-07-16 | 2014-05-29 | Genentech Inc | ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS |
| MY150531A (en) | 2007-07-16 | 2014-01-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| PE20091318A1 (es) | 2008-01-31 | 2009-09-16 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos |
| CN102918040B (zh) | 2010-05-31 | 2015-03-18 | 小野药品工业株式会社 | 6-羟基嘌呤衍生物 |
| FR2976811A1 (fr) * | 2011-06-22 | 2012-12-28 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom |
| RS63121B1 (sr) * | 2011-08-16 | 2022-05-31 | Morphosys Ag | Kombinovana terapija sa anti-cd19 antitelom i analogom purina |
| US20140255427A1 (en) * | 2011-08-16 | 2014-09-11 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| FR2980110A1 (fr) * | 2011-09-20 | 2013-03-22 | Lfb Biotechnologies | Combinaison d'anticorps anti-cd20 et de bendamustine |
| WO2013081016A1 (ja) | 2011-11-29 | 2013-06-06 | 小野薬品工業株式会社 | プリノン誘導体塩酸塩 |
| CN103375132A (zh) * | 2012-04-24 | 2013-10-30 | 长江大学 | 井下旋转冲击式钻井工具 |
| EP3620468A1 (en) | 2013-02-05 | 2020-03-11 | EngMab Sàrl | Method for the selection of antibodies against bcma |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| WO2014195460A1 (en) * | 2013-06-07 | 2014-12-11 | Nordic Nanovector As | Method for upregulating antigen expression |
| JP6528779B2 (ja) | 2014-03-25 | 2019-06-12 | 小野薬品工業株式会社 | びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤 |
| LT3262071T (lt) | 2014-09-23 | 2020-06-25 | F. Hoffmann-La Roche Ag | Anti-cd79b imunokonjugatų naudojimo būdai |
| WO2016163531A1 (ja) | 2015-04-09 | 2016-10-13 | 小野薬品工業株式会社 | プリノン誘導体の製造方法 |
| HUE048939T2 (hu) | 2015-08-03 | 2020-09-28 | Engmab Sarl | Human B sejt érési antigén elleni monoklonális antitestek (BCMA) |
| EP3257866A1 (en) * | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Modified anti-tnf antibody and use thereof in the treatment of ibd |
| WO2018083204A1 (en) | 2016-11-02 | 2018-05-11 | Engmab Sàrl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| JP2020508436A (ja) | 2016-12-07 | 2020-03-19 | プロジェニティ， インコーポレイテッド | 胃腸管の検出方法、装置およびシステム |
| WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| CN113713095A (zh) | 2018-05-23 | 2021-11-30 | 细胞基因公司 | 用于组合使用的抗增殖化合物和针对bcma和cd3的双特异性抗体 |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| JP7287048B2 (ja) | 2019-03-27 | 2023-06-06 | セイコーエプソン株式会社 | ロボット |
| EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| PL348634A1 (en) | 1998-05-15 | 2002-06-03 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| EP3031917A1 (en) | 1999-04-09 | 2016-06-15 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AU2003301445A1 (en) | 2002-10-17 | 2004-05-04 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ES2633311T3 (es) | 2002-12-16 | 2017-09-20 | Genentech, Inc. | Variantes de inmunoglobulina y usos de las mismas |
| CN103540600B (zh) | 2003-01-22 | 2017-12-01 | 罗氏格黎卡特股份公司 | 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途 |
| WO2004103301A2 (en) * | 2003-05-16 | 2004-12-02 | Hybridon, Inc. | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
| US20050054048A1 (en) | 2003-07-29 | 2005-03-10 | Luigi Grasso | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| WO2005027966A2 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
| ME03330B (me) | 2003-11-05 | 2019-10-20 | Roche Glycart Ag | Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| EP1874816A4 (en) | 2005-04-26 | 2010-08-25 | Medimmune Inc | MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING |
| CA2605697A1 (en) | 2005-04-26 | 2006-11-02 | Bioren, Inc. | Method of producing human igg antibodies with enhanced effector functions |
| KR101460932B1 (ko) | 2005-08-26 | 2014-11-12 | 로슈 글리카트 아게 | 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자 |
| NZ568433A (en) * | 2005-10-21 | 2012-07-27 | Gtc Biotherapeutics Inc | Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US20090110688A1 (en) * | 2007-10-24 | 2009-04-30 | Georg Fertig | Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor |
| WO2009083009A2 (en) * | 2008-01-03 | 2009-07-09 | Genmab A/S | Monoclonal antibodies against cd32b |
| CA2749151A1 (en) * | 2009-01-16 | 2010-07-22 | Glaxosmithkline Llc | Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody |
| KR101583107B1 (ko) * | 2009-04-15 | 2016-01-07 | 인비스타 테크놀러지스 에스.에이 알.엘. | 비혼화성 화합물의 혼화성 개선 |
-
2010
- 2010-08-11 TW TW099126813A patent/TWI409079B/zh active
- 2010-08-12 BR BR112012002855A patent/BR112012002855A2/pt not_active Application Discontinuation
- 2010-08-12 PT PT107471682T patent/PT2464382T/pt unknown
- 2010-08-12 PL PL10747168T patent/PL2464382T3/pl unknown
- 2010-08-12 SG SG2012008843A patent/SG178324A1/en unknown
- 2010-08-12 DK DK10747168.2T patent/DK2464382T3/en active
- 2010-08-12 MA MA34585A patent/MA33469B1/fr unknown
- 2010-08-12 CN CN201080035971XA patent/CN102596245A/zh active Pending
- 2010-08-12 MX MX2014015198A patent/MX355849B/es unknown
- 2010-08-12 AR ARP100102968A patent/AR077866A1/es unknown
- 2010-08-12 MY MYPI2012000606A patent/MY163003A/en unknown
- 2010-08-12 RS RS20170647A patent/RS56146B1/sr unknown
- 2010-08-12 JP JP2012524146A patent/JP5646626B2/ja active Active
- 2010-08-12 EP EP10747168.2A patent/EP2464382B1/en active Active
- 2010-08-12 CN CN201710422477.2A patent/CN107261138A/zh active Pending
- 2010-08-12 CA CA2769674A patent/CA2769674C/en active Active
- 2010-08-12 ES ES10747168.2T patent/ES2630158T3/es active Active
- 2010-08-12 NZ NZ597666A patent/NZ597666A/xx unknown
- 2010-08-12 HU HUE10747168A patent/HUE033531T2/hu unknown
- 2010-08-12 SI SI201031491T patent/SI2464382T1/sl unknown
- 2010-08-12 WO PCT/EP2010/004939 patent/WO2011018224A1/en active Application Filing
- 2010-08-12 AU AU2010281866A patent/AU2010281866B2/en active Active
- 2010-08-12 LT LTEP10747168.2T patent/LT2464382T/lt unknown
- 2010-08-12 MX MX2012001782A patent/MX2012001782A/es active IP Right Grant
- 2010-08-12 KR KR1020127006528A patent/KR101425736B1/ko active IP Right Grant
- 2010-08-13 US US12/855,827 patent/US20110165151A1/en not_active Abandoned
- 2010-12-08 UA UAA201202678A patent/UA110096C2/ru unknown
-
2012
- 2012-01-19 CR CR20120036A patent/CR20120036A/es unknown
- 2012-01-26 IL IL217753A patent/IL217753A/en active IP Right Grant
- 2012-02-02 ZA ZA2012/00830A patent/ZA201200830B/en unknown
- 2012-02-08 US US13/368,465 patent/US20120315268A1/en not_active Abandoned
- 2012-02-14 CL CL2012000391A patent/CL2012000391A1/es unknown
-
2013
- 2013-01-18 HK HK18104879.8A patent/HK1245145A1/zh unknown
- 2013-03-06 US US13/787,532 patent/US20140044705A1/en not_active Abandoned
-
2014
- 2014-05-08 US US14/273,148 patent/US20160166688A9/en not_active Abandoned
- 2014-11-04 JP JP2014224221A patent/JP5963013B2/ja active Active
-
2016
- 2016-06-15 JP JP2016118739A patent/JP2016222673A/ja active Pending
-
2017
- 2017-06-27 HR HRP20170972TT patent/HRP20170972T1/hr unknown
- 2017-07-03 CY CY20171100706T patent/CY1119251T1/el unknown
- 2017-10-26 CY CY2017034C patent/CY2017034I1/el unknown
- 2017-10-26 LU LU00045C patent/LUC00045I2/fr unknown
- 2017-10-26 NO NO2017054C patent/NO2017054I1/no unknown
- 2017-10-27 HU HUS1700041C patent/HUS000498I2/hu unknown
- 2017-10-31 LT LTPA2017035C patent/LTPA2017035I1/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2017034I2 (el) | Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη | |
| LTPA2019011I1 (lt) | CGRP antikūnai | |
| HK1221153A1 (zh) | 抗體-藥物綴合物 | |
| SMT201600022B (it) | Pirrolobenzodiazepine e loro coniugati | |
| IL244960A0 (en) | Combination therapy with an apocosylated cd20 antibody with a btk inhibitor | |
| CO7071096A2 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
| BR112015002193A2 (pt) | anticorpos anti-etbr e imunoconjugados | |
| BR112012030311A2 (pt) | anticorpo | |
| RS56268B1 (sr) | Monoklonalno antitelo protiv interleukina-31 kod pasa | |
| BR112013014361A2 (pt) | forma de dosagem | |
| BR112014009055A2 (pt) | pirrolobenzodiazepinas e conjugados alvos | |
| DK3184136T3 (da) | Injektor | |
| CR20140127A (es) | Anticuerpo anti-abtcr | |
| BR112013002297A2 (pt) | anticorpos humanizados seguros e funcionais | |
| BR112013017948A2 (pt) | tubo | |
| HK1180228A1 (zh) | 無岩藻糖基化 抗體與抗 抗體的聯合療法 | |
| FR2958955B1 (fr) | Escalier helicoidal escamotable | |
| BR112013030078A2 (pt) | hipertensão e hiperuricemia | |
| SMT201600367B (it) | Indumento intimo | |
| DE112011104961A5 (de) | Induktiver Sensor | |
| TH0901005583A (th) | แอนติ-igf แอนติบอดี | |
| UY4061Q (es) | Diseño llamas | |
| UY4060Q (es) | Diseño llamas | |
| IT1403021B1 (it) | Pipa |